Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III
18 Years
N/A
Female
Precancerous Condition
Trial Information
Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III
OBJECTIVES:
- Compare the efficacy of SGN-00101 vs placebo in patients with grade II or III cervical
intraepithelial neoplasia.
- Correlate clinical response, as defined by histologic demonstration of lesion
regression, with potential surrogate markers of vaccine efficacy (e.g., spectroscopic
changes in the epithelium, development of human papilloma virus (HPV)-specific mucosal
and systemic T-cell responses, and levels of HPV-specific antibody in cervical
secretions), in patients treated with this drug.
OUTLINE: This is a randomized, double-blind study. Patients are randomized to 1 of 2
treatment arms.
- Arm I: Patients receive SGN-00101 subcutaneously (SC) once a month for 3 consecutive
months in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive placebo SC as in arm I. Patients are followed monthly for 3
months after the last injection and then undergo large loop excision of the
transformation zone under colposcopy at the fourth month. Patients with disease
progression undergo immediate large loop excision.
PROJECTED ACCRUAL: A maximum of 80 patients (40 per treatment arm) will be accrued for this
study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed grade II or III cervical intraepithelial neoplasia
- Confirmed by colposcopy-directed punch biopsy
- Accessible, definable, and entirely visible cervical lesions persisting after biopsy
- Satisfactory colposcopic exam within 3-6 weeks after diagnostic biopsy
- Positive for human papilloma virus 16
- CD4+ counts normal
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0
Life expectancy
- Not specified
Hematopoietic
- No coagulation disorder that requires medical intervention
Hepatic
- Hepatitis B core antigen negative
- Hepatitis C antibody negative
Renal
- Not specified
Cardiovascular
- No cardiovascular disorder that requires medical intervention
Pulmonary
- No respiratory disorder that requires medical intervention
Immunologic
- HIV negative
- Not immunologically compromised
- No prior severe allergic reactions (anaphylactic response) to drugs or any other
allergen
- No immunological disorders including any of the following:
- Lupus
- Diabetes
- Multiple sclerosis
- Myasthenia gravis
- No active systemic infections that require medical intervention
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Willing to undergo a loop electrosurgical excision procedure
- No medical or psychiatric illness that would preclude study treatment, ability to
give informed consent, or study compliance
- No other prior malignancy except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent immunotherapy
- No other concurrent gene therapy
- No concurrent biologic therapy
Chemotherapy
- No concurrent chemotherapy
Endocrine therapy
- More than 30 days since prior systemic steroid therapy
Radiotherapy
- No concurrent radiotherapy
Surgery
- Not specified
Other
- More than 30 days since prior investigational drugs
- No other concurrent investigational drugs
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Principal Investigator
Kristin A. Keefe, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Dana-Farber/Brigham and Women's Cancer Center
Authority:
United States: Federal Government
Study ID:
CDR0000299462
NCT ID:
NCT00060099
Start Date:
May 2003
Completion Date:
Related Keywords:
- Precancerous Condition
- cervical intraepithelial neoplasia grade 2
- cervical intraepithelial neoplasia grade 3
- human papilloma virus infection
- Neoplasms
- Precancerous Conditions
- Cervical Intraepithelial Neoplasia
- Carcinoma in Situ
Name | Location |
|---|---|
| Brigham and Women's Hospital | Boston, Massachusetts 02115 |
